Federal regulators on Tuesday let 23andMe become the first to market a test for three inherited BRCA gene mutations directly to consumers - no doctor's prescription needed. But there are lots of caveats.
For the first time, the Pennsylvania Supreme Court has been asked to take up an issue that has torn American law and politics for three decades: whether illegal drug use during pregnancy can be punished as child abuse.
The opioid addiction crisis has led medical groups to recommend tightening up painkiller prescribing, but getting physicians to comply has been a challenge. A University of Pennsylvania study has found a simple way to nudge emergency department doctors in the right direction: set the electronic medical records system to default to the recommended 10 opioid pills, or about a three-day supply, for acute pain.
The U.S. Food and Drug Administration on Friday approved the first treatment for advanced breast cancer caused by inherited mutations in BRCA genes. The agency initially approved AstraZeneca Pharmaceutical's Lynparza (olaparib tablets) in 2014 to treat advanced ovarian cancer caused by mutations in BRCA1 or BRCA2.
Federal legislation that aims to give desperately ill patients greater access to unapproved drugs reflects a broader effort to weaken medical product regulation, two University of Pennsylvania bioethicists argue in a prominent medical journal.
After reviewing the latest research, the U.S. Food and Drug Administration on Thursday reaffirmed its 2014 warning that power morcellators should rarely be used in gynecological surgery because of the small risk of spreading a hidden uterine cancer.
Marie McCullough covers health and medicine, with a special focus on cancer and women's health issues.